



Figure 1

***N*-(2,3-dimyristyloxypropyl) amide PEG₂₀₀₀ methyl ether (PEG-A-DMA)**



***N*-(2,3-dimyristyloxypropyl) carbamate PEG₂₀₀₀ methyl ether (PEG-C-DMA)**



***N*-(2,3-dimyristyloxypropyl) succinamide PEG₂₀₀₀ methyl ether (PEG-S-DMA)**




Figure 2





Figure 3

Figure 4





Figure 5

Figure 6





Figure 7



In Vivo Transfection of Organs by SPLP and pSPLP (PRO-225)




Figure 9




Figure 10

Timecourse silencing effect of anti-luc siRNA and pL055 SNALP (PEG-A-DMA) on luciferase gene expression in the tumour after a single iv dose of 50 ug of anti-luc siRNA & 50 ug of pL055 in Neuro-2a tumour bearing male AJ mice




Figure 11

Timecourse silencing effect of anti-luc siRNA and pL055 SNALP (PEG-A-DMA) on luciferase gene expression in the tumour after a single iv dose of 50 ug of anti-luc siRNA & 50 ug of pL055 in Neuro-2a tumour bearing male AJ mice




Figure 12

Timecourse silencing effect of anti-luc siRNA and pL055 SNALP (PEG-A-DMA) on luciferase gene expresesion in the tumour after a single iv dose of 50 ug of anti-luc siRnA & 50 ug of pL055 in Neuro-2a tumour bearing male AJ mice




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20

Effect on 48hr Luciferase Gene Expression of SPLP Containing 15mol%
DODMA with Varying Amounts of PEG-C-DMA (PRO-272)




Figure 21




Figure 22




Figure 23